February 12, 2021 11:21 AM EST
Peer Review

Ex-Vi­vid­ion chief Diego Mi­ralles finds 'dream team' at stealthy Flag­ship port­fo­lio com­pa­ny; Astel­las looks in­ward to se­lect CBO and CSO

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Nicole DeFeudis

Editor

Al­most three months af­ter leav­ing Vi­vid­ion Ther­a­peu­tics, where he re­cent­ly signed a $135 mil­lion Roche deal, Diego Mi­ralles has land­ed the top spot on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times